1-20 of 23
Clemens-M. Wendtner
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

MARCKS affects cell motility and response to BTK inhibitors in CLL

Laura Beckmann, Valeska Berg, Clarissa Dickhut, Clare Sun, Olaf Merkel, Johannes Bloehdorn, Sandra Robrecht, Marc Seifert, Alexandra da Palma Guerreiro, Julia Claasen, Stefan Loroch, Matteo Oliverio, Chingiz Underbayev, Lauren Vaughn, Daniel Thomalla, Malte F. Hülsemann, Eugen Tausch, Kirsten Fischer, Anna Maria Fink, Barbara Eichhorst, Albert Sickmann, Clemens M. Wendtner, Stephan Stilgenbauer, Michael Hallek, Adrian Wiestner, René P. Zahedi, Lukas P. Frenzel
Journal: Blood
Blood (2021) 138 (7): 544–556.
https://doi.org/10.1182/blood.2020009165
Published: 2021
Includes: Supplemental data
Journal Articles

Venetoclax and obinutuzumab in chronic lymphocytic leukemia

Clinical Trials & Observations
Kirsten Fischer, Othman Al-Sawaf, Anna-Maria Fink, Mark Dixon, Jasmin Bahlo, Simon Warburton, Thomas J. Kipps, Robert Weinkove, Sue Robinson, Till Seiler, Stephen Opat, Carolyn Owen, Javier López, Kathryn Humphrey, Rod Humerickhouse, Eugen Tausch, Lukas Frenzel, Barbara Eichhorst, Clemens-M. Wendtner, Stephan Stilgenbauer, Anton W. Langerak, Jacque J. M. van Dongen, Sebastian Böttcher, Matthias Ritgen, Valentin Goede, Mehrdad Mobasher, Michael Hallek
Journal: Blood
Blood (2017) 129 (19): 2702–2705.
https://doi.org/10.1182/blood-2017-01-761973
Published: 2017
Includes: Supplemental data
Journal Articles

Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323)

Kirsten Fischer, MD, Othman Al-Sawaf, MD, Anna-Maria Fink, MD, Mark Dixon, BSc MSC, Jasmin Bahlo, Simon Warburton, MSc, Thomas J. Kipps, MD, PhD, Robert Weinkove, MD PhD, Sue Robinson, MD, Martin H. Dreyling, MD PhD, Stephen Opat, MD, Carolyn J. Owen, MD MDes(UK), FRCPC, Javier López, MD PhD, Kathryn Humphrey, PhD, Rod A. Humerickhouse, MD, Eugen Tausch, Barbara Eichhorst, MD, Clemens-M. Wendtner, MD, Anton W. Langerak, Jacques J.M. van Dongen, MD PhD, Matthias Ritgen, Sebastian Boettcher, MD, Stephan Stilgenbauer, Valentin Goede, MD, Mehrdad Mobasher, MD, Michael Hallek
Journal: Blood
Blood (2016) 128 (22): 2054.
https://doi.org/10.1182/blood.V128.22.2054.2054
Published: 2016
Journal Articles

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

Clinical Trials & Observations
Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka, Thorsten Zenz, Marianna Rossi, Konstanze Döhner, Andreas Bühler, Sebastian Böttcher, Matthias Ritgen, Michael Kneba, Dirk Winkler, Eugen Tausch, Patrick Hoth, Jennifer Edelmann, Daniel Mertens, Lars Bullinger, Manuela Bergmann, Sabrina Kless, Silja Mack, Ulrich Jäger, Nancy Patten, Lin Wu, Michael K. Wenger, Günter Fingerle-Rowson, Peter Lichter, Mario Cazzola, Clemens M. Wendtner, Anna M. Fink, Kirsten Fischer, Raymonde Busch, Michael Hallek, Hartmut Döhner
Journal: Blood
Blood (2014) 123 (21): 3247–3254.
https://doi.org/10.1182/blood-2014-01-546150
Published: 2014
Includes: Supplemental data
Journal Articles

Head-To-Head Comparison Of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb In Patients With Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities): Final Stage 2 Results Of The CLL11 Trial

Valentin Goede, MD, Kirsten Fischer, MD, Raymonde Busch, PhD, Anja Engelke, Barbara Eichhorst, MD, Clemens M Wendtner, MD, Tatiana Chagorova, MD, Javier De la Serna, MD, PhD, Marie-Sarah Dilhuydy, MD, Stephen Opat, MD, Carolyn J. Owen, MD, FRCPC, Olga Samoylova, MD, Karl-Anton Kreuzer, MD, Anton W Langerak, PhD, Matthias Ritgen, MD, Stephan Stilgenbauer, MD, Hartmut Döhner, MD, Elina Asikanius, Kathryn Humphrey, Michael K Wenger, MD, Michael Hallek, MD
Journal: Blood
Blood (2013) 122 (21): 6.
https://doi.org/10.1182/blood.V122.21.6.6
Published: 2013
Journal Articles

Cocktail of eternity: HDAC meets miR

Clemens M. Wendtner
Journal: Blood
Blood (2012) 119 (5): 1095–1096.
https://doi.org/10.1182/blood-2011-12-394494
Published: 2012
Journal Articles

Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis

Clinical Trials & Observations
Barbara F. Eichhorst, Kirsten Fischer, Anna-Maria Fink, Thomas Elter, Clemens M. Wendtner, Valentin Goede, Manuela Bergmann, Stephan Stilgenbauer, Georg Hopfinger, Matthias Ritgen, Jasmin Bahlo, Raymonde Busch, Michael Hallek, for the German CLL Study Group (GCLLSG)
Journal: Blood
Blood (2011) 117 (6): 1817–1821.
https://doi.org/10.1182/blood-2010-04-282228
Published: 2011
Includes: Supplemental data
Journal Articles

Detection of a novel truncating Merkel cell polyomavirus large T antigen deletion in chronic lymphocytic leukemia cells

Brief Report
N. Deepa Pantulu, Christian P. Pallasch, Anna Kordelia Kurz, Ahmad Kassem, Lukas Frenzel, Sebastian Sodenkamp, Hans Michael Kvasnicka, Clemens M. Wendtner, Axel zur Hausen
Journal: Blood
Blood (2010) 116 (24): 5280–5284.
https://doi.org/10.1182/blood-2010-02-269829
Published: 2010
Journal Articles

Final Results of a Phase Ib Trial of Atacicept to Neutralize APRIL and BLyS in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia (CLL).

David M Kofler, MD, Barbara B Gawlik, MD, Thomas Elter, MD, Athos Gianella-Borradori, MD, Clemens M Wendtner, MD, Michael Hallek, MD
Journal: Blood
Blood (2009) 114 (22): 2373.
https://doi.org/10.1182/blood.V114.22.2373.2373
Published: 2009
Journal Articles

CD28 Costimulation of Effector T Cells During An Anti-Tumor Attack Sustains Its Repression by Regulatory T Cells Which Can Be Overcome by Preventing Lck Activation.

David M Kofler, MD, Markus Chmielewski, PhD, Tobias Riet, Andreas Hombach, MD, Michael Hallek, MD, Clemens M Wendtner, MD, Hinrich Abken, MD
Journal: Blood
Blood (2009) 114 (22): 3569.
https://doi.org/10.1182/blood.V114.22.3569.3569
Published: 2009
Journal Articles

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

Clinical Trials & Observations
Barbara F. Eichhorst, Raymonde Busch, Stephan Stilgenbauer, Martina Stauch, Manuela A. Bergmann, Matthias Ritgen, Nicole Kranzhöfer, Robert Rohrberg, Ulrike Söling, Oswald Burkhard, Anne Westermann, Valentin Goede, Carmen D. Schweighofer, Kirsten Fischer, Anna-Maria Fink, Clemens M. Wendtner, Günter Brittinger, Hartmut Döhner, Bertold Emmerich, Michael Hallek, the German CLL Study Group (GCLLSG)
Journal: Blood
Blood (2009) 114 (16): 3382–3391.
https://doi.org/10.1182/blood-2009-02-206185
Published: 2009
Includes: Supplemental data
Journal Articles

Statins Inhibit the Function of Human Antigen-Presenting Cells

Alexander Shimabukuro-Vornhagen, MD, Tanja Liebig, Shahram Zoghi, Clemens M Wendtner, MD, Michael S von Bergwelt-Baildon, MD
Journal: Blood
Blood (2008) 112 (11): 2560.
https://doi.org/10.1182/blood.V112.11.2560.2560
Published: 2008
Journal Articles

The Performance of Computed Tomography (CT) Scans or Ultrasound Has No Clinical Relevance in Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Metaanalysis from Three Phase III Studies of the German CLL Study Group (GCLLSG).

Barbara F. Eichhorst, MD, Kirsten Fischer, MD, Anna- Maria Fink, MD, Thomas Elter, MD, Clemens M Wendtner, MD, Raymonde Busch, Dipl., math., Michael Hallek, German CLL Study Group
Journal: Blood
Blood (2008) 112 (11): 1053.
https://doi.org/10.1182/blood.V112.11.1053.1053
Published: 2008
Journal Articles

Biologic and Clinical Markers for Outcome after Fludarabine (F) or F Plus Cyclophosphamide (FC) - Comprehensive Analysis of the CLL4 Trial of the GCLLSG.

Stephan Stilgenbauer, Barbara F. Eichhorst, Raymonde Busch, Thorsten Zenz, Dirk Winkler, Andreas Bühler, Valentin Goede, Clemens M Wendtner, Peter Lichter, Berthold Emmerich, Michael Hallek, Hartmut Döhner
Journal: Blood
Blood (2008) 112 (11): 2089.
https://doi.org/10.1182/blood.V112.11.2089.2089
Published: 2008
Journal Articles

Preliminary Results of a Phase 1/2, Multi-Center, Open-Label Study (CLL- 001) Investigating a Stepwise Dose-Escalation Schedule of Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Clemens M Wendtner, MD, Daruka Mahadevan, MD, PhD, Stephan Stilgenbauer, MD, PhD, Olga Frankfurt, MD, Adrian Bloor, PhD, MRCP, FRCPath, Francesc Bosch, MD, PhD, Lutz Uharek, Richard R Furman, MD, Marco Gobbi, John G. Gribben, MD, DSc, Eva K. Kimby, MD, PhD, Mikkael A. Sekeres, MD, MS, Larry D. Cripe, MD, Elyane Lombardy, Sheetal Shah, Laure A Moutouh-de Parseval, Asher Alban Chanan-Khan, MD, Robert D. Knight, MD
Journal: Blood
Blood (2008) 112 (11): 2104.
https://doi.org/10.1182/blood.V112.11.2104.2104
Published: 2008
Journal Articles

No Significant Clinical Benefit of First Line Therapy with Fludarabine (F) in Comparison to Chlorambucil (Clb) in Elderly Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Phase III Study of the German CLL Study Group (GCLLSG).

Barbara F. Eichhorst, MD, Raymonde Busch, Martina Stauch, MD, Manuela Bergmann, MD, Matthias Ritgen, MD, Nicole Kranzhöfer, MD, Carmen D. Schweighofer, MD, Kirsten Fischer, MD, Anna-Maria Fink, MD, Paula Cramer, Valentin Goede, MD, Clemens M. Wendtner, MD, Michael Hallek, MD, GCLLSG
Journal: Blood
Blood (2007) 110 (11): 629.
https://doi.org/10.1182/blood.V110.11.629.629
Published: 2007
Journal Articles

The Src-Abl Kinase Inhibitor Dasatinib (BMS-354825) Shows Anti-Proliferative and Anti-Apoptotic Effects in Chronic Lymphocytic Leukemia (CLL) Cells In Vitro .

Aditya Veldurthy, MSc, Michaela Patz, Dipl., Biol., Christian P. Pallasch, MD, Clemens M. Wendtner, MD, Michael Hallek, MD, Gunter F. Krause, PhD
Journal: Blood
Blood (2007) 110 (11): 3101.
https://doi.org/10.1182/blood.V110.11.3101.3101
Published: 2007
Journal Articles

Impact of Regulatory T Cells on Antigen Specific T Cell Response Using Recombinant Chimeric T Cell Receptors In Vivo.

David M. Kofler, MD, Markus Chmielewski, Heike Koehler, Tobias Riet, Patrick Schmidt, Gunter Rappl, Andreas Hombach, MD, Michael Hallek, MD, Clemens M. Wendtner, MD, Hinrich Abken, MD
Journal: Blood
Blood (2006) 108 (11): 5475.
https://doi.org/10.1182/blood.V108.11.5475.5475
Published: 2006
Journal Articles

Overexpression of Lipases Enables Specific Cytotoxicity by the Lipase Inhibitor Orlistat in Chronic Lymphocytic Leukemia Cells.

Christian P. Pallasch, MD, Janine Schwamb, Alexandra Schulz, Svenja Debey, PhD, David Kofler, MD, Joachim L. Schultze, MD, Michael Hallek, MD, Alfred Ultsch, PhD, Clemens M. Wendtner, MD
Journal: Blood
Blood (2006) 108 (11): 2800.
https://doi.org/10.1182/blood.V108.11.2800.2800
Published: 2006
Journal Articles

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

Clinical Trials & Observations
Barbara F. Eichhorst, Raymonde Busch, Georg Hopfinger, Rita Pasold, Manfred Hensel, Cordelia Steinbrecher, Siegfried Siehl, Ulrich Jäger, Manuela Bergmann, Stephan Stilgenbauer, Carmen Schweighofer, Clemens M. Wendtner, Hartmut Döhner, Günter Brittinger, Bertold Emmerich, Michael Hallek, the German CLL Study Group
Journal: Blood
Blood (2006) 107 (3): 885–891.
https://doi.org/10.1182/blood-2005-06-2395
Published: 2006